WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 7, 544-554. Research Article ISSN 2277–7105

CELL CYCLE MODULATORS REGULATING THE BASIC UNIT OF LIFE FOR DISEASE TREATMENT AND TISSUE REGENERATION

[1]Prof. Sandip Pagare, [2]Prof. Ashwini Pagare, [3]Miss. Shrunjal Wankhede, [4]Mr. Lokesh Mahale, [5]Mr. Hemraj Ahire, [6]Miss. Pratibha Kuwar

Assistant Professor, Rupesh Badhan Institute of Pharmacy Pimpalner Tal-Sakri Dist-Dhule.

Article Received on
09 February 2024,

Revised on 29 Feb. 2024,
Accepted on 20 March 2024

DOI: 10.20959/wjpr20247-31769

***Corresponding Author**
Prof. Sandip Pagare
Assistant Professor, Rupesh Badhan Institute of Pharmacy Pimpalner Tal-Sakri Dist-Dhule.

ABSTRACT

The intricate dance of cell division, known as the cell cycle, is fundamental to all living organisms. This meticulously orchestrated process ensures the precise duplication and inheritance of genetic material during cell proliferation. Disruptions in the cell cycle are hallmarks of various diseases, including cancer, and hinder tissue regeneration. Therefore, targeting cell cycle modulators presents a promising therapeutic strategy for disease treatment and tissue repair. This review article delves into the diverse array of cell cycle modulators, exploring their mechanisms of action and potential applications in various disease contexts. We discuss the therapeutic implications of targeting key regulators like cyclin-dependent kinases (CDKs), their cyclin partners, and checkpoint proteins. Additionally, we explore the potential of harnessing cell cycle modulators to promote tissue regeneration following injury or disease. By providing a comprehensive overview of cell cycle modulators and their therapeutic potential, this review aims to stimulate further research and development efforts towards novel therapeutic strategies for an array of diseases and tissue regeneration challenges.

KEYPOINTS: cell cycle; disease treatment; tissue regeneration; cell division; cyclin-dependent kinases (CDKs); cancer; cell cycle modulator.

INTRODUCTION

The cell cycle, or the cell division cycle, is the series of events that take place in a cell that drive it to divide and produce two new daughter cells. The typical cell cycle in eukaryotes is composed of four phases including the G1, S, G2, and M phase. G1, S, and G2 together are

called interphase. M phase is comprised of mitosis,in which the cell's nucleus divides, and cytokinesis, in which the cell's cytoplasm divides to form two daughter cells. Mitosis and cytokinesis are tightly coupled together. Mitosis is further divided into five subphases including prophase, prometaphase, metaphase, anaphase, and telophase (Figure 1).



Figure 1: Diagram to illustrate a complete cell cycle progression through four cell cycle phases (G1, S, G2, and M) and three major checkpoints (G1/S, G2/M, and SAC). M phase is further divided into Prophase, Prometaphase, Metaphase, Anaphase, and Telophase.

A cell cycle modulator is a substance that influences the progression of a cell through its various stages in the cell cycle. These modulators can either promote or inhibit cell cycle progression, playing a crucial role in cell growth, development, and reproduction. Examples include cyclins, cyclin-dependent kinases (CDKs), and checkpoint proteins. Their precise regulation is vital for maintaining normal cell function and preventing uncontrolled cell division, which is characteristic of diseases like cancer (figure.2).



Figure 2: Cell cycle regulation.

Cell cycle regulation

The cell cycle is an ordered set of events that ultimately leads to cell growth and division. The cell cycle in eukaryotic cells has traditionally been divided into two major phases: interphase and mitosis (M phase). Interphase is composed of three subphases: G1, S, and G2. In the G1 phase, the biosynthesis of RNA and protein is mainly carried out to prepare for the DNA synthesis in the S phase. During this period, the synthesis of mRNA, rRNA, and tRNA accelerates, leading to the formation of structural proteins and enzyme proteins. The S phase refers to the period from the beginning to completion of DNA replication. The most important feature of this period is the replication of DNA and the synthesis of chromosomal proteins such as histones and non-histone proteins. Through DNA replication, genetic information is accurately transmitted to the daughter cells of M phase division to ensure the stability of genetic traits. Therefore, the S phase is the most critical phase in the cell cycle. Many chemotherapeutic drugs mainly act on the S phase of cells. The G2 phase is the period from the completion of DNA replication to the beginning of mitosis. During the G2 phase, the synthesis of RNA and proteins directly related to mitosis, such as microfilaments, tubulin, and important factors in mitosis regulation, occur to prepare for mitosis. The M phase is divided into the prophase, metaphase, anaphase, and telophase, which is the process of dividing chromosomes into two daughter cells precisely and evenly. The DNA and proteins of the cell are divided equally into two cells, completing the process of cell replication. In the process of cell growth and reproduction, the end of the previous cycle is generally the beginning of the next cycle. However, some cells do not enter the next cycle but temporarily exit the cell cycle and enter the G0 phase. Cells in the G0 phase will transform to the G1 phase under the influence of mitogens. Cell cycle regulation is a series of complex mechanisms involving the regulation of a variety of cyclins, cyclin-dependent kinases, cell cycle checkpoints, and cell cycle signaling pathways.

Tissue regeneration

Tissue regeneration is the process by which damaged or injured tissues in the body repair and restore themselves. It involves the activation and proliferation of cells to replace damaged or lost tissue, promoting healing and functional recovery. Various factors, such as growth factors and cell signaling pathways, play crucial roles in regulating this complex biological process. Researchers explore ways to enhance tissue regeneration for medical applications, including regenerative medicine and tissue engineering.

It involves the proliferation and differentiation of cells to replace damaged tissue and restore normal function. This natural healing mechanism occurs in various tissues, such as skin, liver, and bone. Researchers explore ways to enhance and harness this process for medical advancements, including regenerative medicine techniques and stem cell therapies.



Figure 3

History

The history of the cell cycle dates back to the late 19th century when advancements in microscopy allowed scientists to observe cell division. Walther Flemming's work in 1882 identified and described mitosis, revealing distinct phases of cell division.

In the early 20th century, Edmund Beecher Wilson coined the term "chromosome" and emphasized their role in heredity. Theodor Boveri, around 1902, proposed the idea that chromosomes carry genetic information.

Mid-20th century research by Arthur Pardee in the 1950s delineated the cell cycle into three phases (G1, S, G2). In the 1960s, Howard Temin discovered proteins that control cell division.

The late 20th century saw significant progress with the identification of cyclins by Tim Hunt, Lee Hartwell, and Paul Nurse. Their work laid the foundation for understanding cyclin-

dependent kinases (CDKs) as crucial regulators. Ongoing research in the molecular and genetic aspects of the cell cycle, including contributions from scientists like Robert Weinberg, continues to refine our understanding, emphasizing the intricate regulatory mechanisms governing cell division.



Figure 2: Timeline of major discoveries in the early cell cycle research.

Progress in cell cycle modulator

Cell cycle modulators involves identifying compounds or agents that can selectively influence key regulatory proteins and checkpoints in the cell cycle. Researchers explore these modulators for potential therapeutic applications, particularly in the treatment of diseases such as cancer.

Progress in this field often includes

Target identification: Identifying specific proteins or pathways within the cell cycle that can be targeted for modulation.

Screening compounds: High-throughput screening of chemical libraries to find molecules that interact with the identified targets.

Validation studies: Confirming the effectiveness and safety of potential modulators through in vitro and in vivo studies.

Structure-Activity Relationship (SAR) Studies: Optimizing the chemical structure of the identified compounds to enhance their efficacy and specificity.

Clinical trials: Conducting clinical trials to evaluate the safety and efficacy of promising cell cycle modulators in human subjects.

Regulatory approval: Submitting data to regulatory authorities for approval of new drugs or therapies.

It's advisable to check recent scientific literature or updates from pharmaceutical companies for the latest developments in cell cycle modulator research. Keep in mind that progress in this area can occur rapidly, and new findings may have emerged since my last knowledge update in January 2022.

Disease and Treatment

Cell cycle dysregulation can lead to various diseases. For example, breast cancer, lung cancer, and leukemia. Additionally, certain genetic disorders and neurodegenerative diseases may arise from abnormal cell cycle regulation. uncontrolled cell division due to abnormal cell cycle modulation is a hallmark of cancer. On the other hand, disruptions in the cell cycle can also contribute to conditions like neurodegenerative diseases and autoimmune disorders. Understanding and targeting cell cycle modulators are crucial for developing treatments for these diseases.

Cancer: Dysregulation of the cell cycle, leading to uncontrolled cell division, is a fundamental characteristic of cancer. It can occur in virtually any organ or tissue of the body. The development of cancer involves genetic mutations that accumulate over time, leading to changes in normal cell regulation mechanisms.

There are various types of cancer, each with unique characteristics and risk factors. Carcinomas arise from epithelial cells, while sarcomas develop from connective tissues. Leukemias affect blood and bone marrow, and lymphomas involve the lymphatic system.

Risk factors for cancer include genetic predisposition, exposure to carcinogens (e.g., tobacco smoke, UV radiation), unhealthy lifestyle choices (e.g., poor diet, lack of physical activity), and certain infections (e.g., human papillomavirus, hepatitis).

Neurodegenerative diseases: Altered cell cycle regulation has been implicated in neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.

Abnormalities in cell cycle control mechanisms may contribute to the development of autoimmune diseases by affecting immune cell function.

Disease can sometimes trigger tissue regeneration as part of the body's healing response. For instance, during inflammation, certain cells promote tissue repair and regeneration to restore normal function.

In some cases, aberrant tissue regeneration can contribute to autoimmune diseases like rheumatoid arthritis. The body's immune system mistakenly targets healthy tissues, leading to inflammation and, in some instances, the need for regeneration processes that can exacerbate the condition.

Treatment neurodegenerative

Diagnosing neurodegenerative diseases often involves a combination of clinical evaluation, medical history, neurological exams, and various tests. Imaging studies like MRI or PET scans can reveal structural changes in the brain, while cerebrospinal fluid analysis may detect specific biomarkers. Genetic testing can also play a role in some cases. Diagnosis is typically challenging and may require collaboration between neurologists and other specialists. If you have specific questions about a particular disease or aspect of diagnosis

Autoimmune disorders: Diagnosing autoimmune disorders often involves a combination of medical history review, physical exams, and specific blood tests to detect antibodies or abnormal immune system activity. Imaging studies and biopsies may be used to assess organ damage or inflammation. Consultation with a rheumatologist or immunologist is crucial for accurate diagnosis and appropriate management.

Cancer: various methods involve in the diagnosis of cancer like a chemotherapy, radiotherapy, Hormone Therapy, Hyperthermia etc.

Chemotherapy

Chemotherapy is a medical treatment that uses drugs to kill or slow the growth of rapidly dividing cells, including cancer cells. The primary goal of chemotherapy is to eliminate cancer cells throughout the body, preventing their spread and recurrence. This treatment can be administered orally or intravenously, targeting both localized and systemic cancers.

Mechanism of action

Chemotherapy drugs interfere with the cell cycle, disrupting the process of cell division and inhibiting the growth of cancer cells.

They target rapidly dividing cells, but unfortunately, normal healthy cells that also divide quickly, such as hair follicles and cells lining the digestive tract, can be affected as well, leading to common side effects.

Types of chemotherapy

Adjuvant chemotherapy: Given after primary treatments like surgery to eliminate remaining cancer cells.

Neoadjuvant chemotherapy: Administered before surgery to shrink tumors and facilitate surgical removal.

Palliative chemotherapy: Aimed at relieving symptoms and improving the quality of life in advanced cancer cases.

Administration

Chemotherapy can be administered through various routes, including oral pills, intravenous injections, intramuscular injections, or directly into specific body cavities.

Side effects

Common side effects include nausea, fatigue, hair loss, and an increased risk of infections due to a weakened immune system.

Individual reactions vary, and some people may experience more severe side effects than others.

Combination therapies

Often, a combination of different chemotherapy drugs is used to maximize effectiveness and minimize resistance.

The choice of drugs depends on the type and stage of cancer, as well as the patient's overall health.

Monitoring and Adjustments

Regular monitoring of blood counts and other vital parameters is crucial during chemotherapy. Treatment plans may be adjusted based on the response and side effects experienced by the patient.

Duration of treatment

The duration of chemotherapy varies depending on the type and stage of cancer.

Some treatments involve cycles, with periods of rest between to allow the body to recover.

Considerations and Precautions

Chemotherapy may impact fertility, and patients are often counseled on fertility preservation options before treatment.

It's important for patients to communicate openly with their healthcare team to manage side effects and emotional challenges.

Advancements in chemotherapy

Ongoing research aims to develop targeted therapies that focus on specific molecules involved in cancer growth, minimizing damage to healthy cells.

In conclusion, chemotherapy remains a critical component in the multimodal approach to cancer treatment, playing a pivotal role in either curing or controlling the disease. Despite its challenges, ongoing advancements seek to enhance its efficacy while minimizing adverse effects.

CONCLUSION

In conclusion, the precise control of cell cycle modulators stands as a critical determinant in addressing diseases and fostering tissue regeneration. Manipulating these fundamental processes provides a strategic approach for developing innovative treatments, offering potential breakthroughs in the realms of both medical intervention and regenerative therapies.

RESULT

Exploring cell cycle modulators is crucial for disease treatment and tissue regeneration. Understanding and manipulating these regulators can potentially lead to innovative therapeutic approaches, addressing various medical challenges.

REFERENCE

1. M. Ruas et al. The p16INK4a/CDKN2A tumor suppressor and its relatives Biochim Biophys Acta, 1998.
2. H.S. Zhang et al. Active transcritional repression by pRb-E2F complex mediates G1 arrest triggered by p16INK4a, TGF beta, and contact inhibition Cell, 1999.
3. Sherr CJ Cancer cell cycles. Science, 1996; 274: 1672-1677. Scopus (5042)
4. Panda S.K., Ray S., Nayak S., Behera S., Bhanja S., Acharya V. A review on cell cycle

checkpoints in relation to cancer. J. Med. Sci, 2019; 5: 88–95. doi: 10.5005/jp-journals-10045-00138.

5. Jones S.M., Kazlauskas A. Connecting signaling and cell cycle progression in growth factor-stimulated cells. Oncogene, 2000; 20: 5558–5567. doi: 10.1038/sj.onc.1203858.
6. Paweletz N. Walther flemming: Pioneer of mitosis research. Nat. Rev. Mol. Cell Biol, 2001; 2: 72–75. doi: 10.1038/35048077
7. Liang Z., Zickler D., Prentiss M., Chang F.S., Witz G., Maeshima K., Kleckner N. Chromosomes progress to metaphase in multiple discrete steps via global compaction/expansion cycles. Cell, 2015; 161: 1124–1137.
8. U. Lehmann et al. Quantitative assessment of promoter hypermethylation during breast cancer development Am J Pathol, 2002.
9. Satyanarayana A., Kaldis P. Mammalian cell-cycle regulation: Several cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene, 2009; 28: 2925–2939.
10. Barnum K.J., O′Connell M.J. Cell cycle regulation by checkpoints. Methods Mol. Biol, 2014; 1170: 29–40. doi: 10.1007/978-1-4939-0888-2_2.
11. Tentori L., Ricci-Vitiani L., Muzi A., Ciccarone F., Pelacchi F., Calabrese R., Runci D., Pallini R., Caiafa P., Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer, 2014; 14: 151. doi: 10.1186/1471-2407-14-151.
12. Chen X.X., Xie F.F., Zhu X.J., Lin F., Pan S.S., Gong L.H., Qiu J.G., Zhang W.J., Jiang Q.W., Mei X.L., et al. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget, 2015; 6: 14926–14939. doi: 10.18632/oncotarget.3717.
13. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med, 2008; 359: 906–917.
14. Guo, Y.; Stacey, D.W.; Hitomi, M. Post-transcriptional regulation of cyclin d1 expression during g2 phase. Oncogene, 2002; 21: 7545–7556.
15. Blasina, A.; de Weyer, I.V.; Laus, M.C.; Luyten, W.H.; Parker, A.E.; McGowan, C.H. A human homologue of the checkpoint kinase cds1 directly inhibits cdc25 phosphatase. Curr. Biol, 1999.
16. Lee S.Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis, 2016; 3: 198–210. doi: 10.1016/j.gendis.2016.04.007.

17. Galluzzi L, Kepp O, Vander Heiden MG & Kroemer G Metabolic targets for cancer therapy. Nat Rev Drug Discov, 2013; 12: 829–846.